Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bios Three
- Development stage
- Unknown
- Lead developer
- Toa Pharmaceuticals
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bios Three is a probiotic combination product developed by Toa Pharmaceutical, containing three symbiotic bacterial strains: *Enterococcus faecium* T-110 (lactic acid bacteria), *Clostridium butyricum* TO-A (butyric acid bacteria), and *Bacillus mesentericus* TO-A (saccharolytic bacteria). These strains work synergistically to regulate intestinal flora; *Bacillus mesentericus* promotes the growth of *Enterococcus faecium*, which produces lactic acid and lowers intestinal pH, thereby facilitating the growth of *Clostridium butyricum*. *Clostridium butyricum* produces butyric acid, a key energy source for colonic epithelial cells that supports intestinal barrier function. The product is approved in Japan for the treatment of gastrointestinal symptoms such as diarrhea, constipation, and abdominal bloating. It is also being investigated in clinical trials for its potential to modulate the intestinal and vaginal microbiota in pregnant women to prevent pregnancy-associated complications.
- Brand names
- Bios ThreeBio-Threeビオスリー
- Other names
- Enterococcus faecium + Clostridium butyricum + Bacillus mesentericus
02
Targets
IEB (Colonic epithelial barrier and mucus layer)
Beyond the preview
Go deeper on Bios Three.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bios Three.